EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim–Sulfamethoxazole Resistance in Burkholderia thailandensis

Sophie Guillier iD, Christine Lazennec-Schurdevin, Lou Mondange, Véronique Sarilar iD, Mélissa Marchandeau, Chloé Lemoigne, Ombeline Lamer, Mathilde Lescat, Emmanuelle Schmitt, Yves Mechulam, Julian Garrec, Fabrice Biot

ACS Infectious Diseases · 14.08.2026 · 12 (8) · 2627-2641

DOI: 10.1021/acsinfecdis.5c01132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 05.08.2026. Verfasst von Sophie Guillier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Unité Bactériologie, Département Microbiologie et Maladies Infectieuses, CNR-LE Charbon, UMR-MD1-Inserm 1261, Institut de Recherche Biomédicale des A…. Hauptthemen laut MEDLINE: Tetrahydrofolate Dehydrogenase, Burkholderia, Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Bacterial Agents. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence de l'innovation de D?fense, Agence de l'innovation de Défense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trimethoprim–sulfamethoxazole (SXT) remains central to melioidosis eradication therapy, yet the genetic basis of resistance evolution in Burkholderia pseudomallei is not fully defined. Using Burkholderia thailandensis as a biosafe surrogate, we subjected populations to stepwise in vitro evolution under increasing SXT concentrations. Whole-genome sequencing revealed rapid population diversification followed by selective sweeps leading to fixation of fitter resistant variants. Early adaptation involved mutations in regulators of RND efflux systems and folate-associated genes, consistent with multifactorial resistance. Despite this heterogeneity, all evolutionary trajectories converged on a single nonsynonymous substitution, I99L, in dihydrofolate reductase (DHFR/FolA), which rose to fixation at high SXT concentrations. This substitution mirrors changes reported in SXT-resistant B. pseudomallei isolates from chronic infections. Allelic reconstruction demonstrated that Bt-DHFR(I99L) is sufficient to confer a 4- to 16-fold increase in trimethoprim MIC. Biochemical and structural analyses showed preserved catalytic activity but reduced trimethoprim binding, consistent with an allosteric resistance mechanism. Together, these findings establish DHFR as a dominant evolutionary target under SXT pressure and support B. thailandensis as a robust model for dissecting resistance evolution in B. pseudomallei.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tetrahydrofolate DehydrogenaseBurkholderiaTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsDrug Resistance, BacterialMutationEvolution, MolecularMicrobial Sensitivity TestsHumansBacterial Proteins

Stichwörter der Autor:innen

Burkholderia pseudomalleiBurkholderia thailandensisDHFRX-ray crystallizationantibiotic resistance mechanismmelioidosistrimethoprim

Substanzen

Tetrahydrofolate DehydrogenaseTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsBacterial Proteins

Autor:innen und Institutionen

  • Unité Bactériologie, Département Microbiologie et Maladies Infectieuses, CNR-LE Charbon, UMR-MD1-Inserm 1261, Institut de Recherche Biomédicale des Armées (IRBA), Brétigny-Sur-Orge91220, France.
  • Laboratoire de Biologie Structurale de la Cellule (BIOC), CNRS, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau91120, France.
  • Institut de Recherche Biomédicale des Armées (IRBA), Brétigny-Sur-Orge91220, France.
  • Pharmacie Centrale des Armées, Fleury-les-Aubrais45404, France.
  • UCP, ENSTA, Institut Polytechnique de Paris, Palaiseau91120, France.
  • Direction Centrale du Service de Santé des Armées (DCSSA), Paris75015, France.

ORCID-Profile: Sophie Guillier, Véronique Sarilar

Förderung

  • Agence de l'innovation de D?fense
  • Agence de l'innovation de Défense

Zitieren

APA

Guillier, S., Lazennec-Schurdevin, C., Mondange, L., Sarilar, V., Marchandeau, M., Lemoigne, C., Lamer, O., Lescat, M., Schmitt, E., Mechulam, Y., Garrec, J., & Biot, F. (2026). Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim–Sulfamethoxazole Resistance in Burkholderia thailandensis. ACS Infectious Diseases, 12(8), 2627-2641. https://doi.org/10.1021/acsinfecdis.5c01132

Vancouver

Guillier S, Lazennec-Schurdevin C, Mondange L, Sarilar V, Marchandeau M, Lemoigne C, et al. Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim–Sulfamethoxazole Resistance in Burkholderia thailandensis. ACS Infectious Diseases. 2026;12(8):2627-2641. doi:10.1021/acsinfecdis.5c01132

BibTeX
@article{Guillier2026,
  author = {Guillier, Sophie and Lazennec-Schurdevin, Christine and Mondange, Lou and Sarilar, Véronique and Marchandeau, Mélissa and Lemoigne, Chloé and Lamer, Ombeline and Lescat, Mathilde and Schmitt, Emmanuelle and Mechulam, Yves and Garrec, Julian and Biot, Fabrice},
  title = {Evolutionary Convergence on a Dihydrofolate Reductase Mutation Drives Trimethoprim–Sulfamethoxazole Resistance in Burkholderia thailandensis},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {8},
  pages = {2627--2641},
  doi = {10.1021/acsinfecdis.5c01132}
}
Kostenlos starten →